BACKGROUND: Eslicarbazepine acetate (ESL, Aptiom®) is a once-daily (QD) anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). It is extensively converted after oral administration to eslicarbazepine, and is believed to exert its effect through inhibition of voltage-gated sodium channels. The possible role of ESL as monotherapy to treat POS has not yet been established. METHODS: This study was an 18-week, multicenter, randomized double-blind trial of gradual conversion to ESL monotherapy in adults with POS not well controlled by 1-2 antiepileptic drugs (AEDs), using historical data as the control. The study comprised an 8-week baseline period, a 2-week titration period, a 6-week AED conversion period, a 10-week monotherapy period, and either a 1-week taper period or optional entry to an open-label extension study. The primary endpoint compared the Kaplan-Meier (KM)-estimated 112-day exit rate with a threshold value calculated from the historical controls. RESULTS: There were 172 randomized patients; 154 (90%) entered the AED conversion period and 121 (70%) completed the study. The KM-estimated exit rates [confidence interval (CI)] were 15.6% [8.1-28.7%] for ESL 1200 mg, and 12.8% [7.5-21.5%] for ESL 1600 mg. The upper limits of the 95% CI KM-estimates were below the pre-specified threshold for historical control of 65.3%, indicating that ESL was efficacious in reducing seizure-related exits, compared with historical control. During the 18-week double-blind treatment period, median reductions in standardized seizure frequency occurred with ESL 1200 mg (36.1%) and ESL 1600 mg (47.5%). The responder rates (a 50% or greater reduction in seizure frequency from baseline) during the 18-week double-blind period and the monotherapy period, respectively, were 35.2% and 38.9% for ESL 1200 mg, and 46.0% and 46.0% for ESL 1600 mg. The overall adverse event profile was consistent with the known safety profile of ESL. CONCLUSIONS: These findings indicate that ESL monotherapy (1200 and 1600 mg QD) was efficacious and well tolerated in this study. TRIAL REGISTRATION: NCT01091662 ; EudraCT No. 2010-018684-42.

CTC Rychnov nad Kněznou s r o Rychnov nad Kneznou Czech Republic

Department of Neurology Temple University School of Medicine Philadelphia PA USA

Neuro Pain Medical Center Fresno CA USA

Sunovion Pharmaceuticals Inc Marlborough MA USA

See more in PubMed

Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy – a review. Epilepsy Res. 2009;85:31–45. doi: 10.1016/j.eplepsyres.2009.03.003. PubMed DOI PMC

Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet. 2006;367:1087–100. doi: 10.1016/S0140-6736(06)68477-8. PubMed DOI

Perucca E. Designing clinical trials to assess antiepileptic drugs as monotherapy. CNS Drugs. 2008;22:917–38. doi: 10.2165/00023210-200822110-00003. PubMed DOI

Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 2011;10:446–56. doi: 10.1016/S1474-4422(11)70047-3. PubMed DOI

St. Louis EK, Rosenfeld WE, Bramley T. Antiepileptic drug monotherapy: the initial approach in epilepsy management. Curr Neuropharmacol. 2009;7:77–82. doi: 10.2174/157015909788848866. PubMed DOI PMC

Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007;6:793–804. doi: 10.1016/S1474-4422(07)70215-6. PubMed DOI

Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol. 2008;64:267–73. doi: 10.1007/s00228-007-0414-1. PubMed DOI

Brown ME, El-Mallakh RS. Role of eslicarbazepine in the treatment of epilepsy in adults with partial-onset seizures. Ther Clin Risk Manag. 2010;6:103–9. PubMed PMC

Hebeisen S, Brady K, Konrad D, Soares-da-Silva P. Inhibitory effects of eslicarbazepine acetate and its metabolites against neuronal voltage-gated sodium channels. Epilepsia. 2011;52(s6):257–8.

Prescribing information . Aptiom® (eslicarbazepine acetate) Marlborough MA, USA: Sunovion Pharmaceuticals Inc; 2013.

Nunes T, Rocha JF, Falcão A, Almeida L, Soares-da-Silva P. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia. 2013;54:108–16. doi: 10.1111/j.1528-1167.2012.03595.x. PubMed DOI

Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010;89:278–85. doi: 10.1016/j.eplepsyres.2010.01.014. PubMed DOI

Elger C, Halasz P, Maia J, Almeida L, Soares-da-Silva P. BIA-2093-301 Investigators Study Group: Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009;50:454–63. doi: 10.1111/j.1528-1167.2008.01946.x. PubMed DOI

Sperling M, Harvey J, Biraben A, Galimberti C, Kowacs P, Hong SB, et al. Adjunctive eslicarbazepine acetate in patients with refractory partial-onset seizures: Efficacy results of a 12 week randomized placebo-controlled study. Abst. 3.210. Epilepsy Curr. 2014;14(s1):395.

Abou-Khalil B, Rogin JB, Biraben A, Galimberti C, Kowacs P, Hong SB, et al. Eslicarbazepine acetate as adjunctive therapy in patients with refractory partial-onset seizures: Safety results of a 12-week randomized placebo-controlled study. Abst. 2.128. Epilepsy Curr. 2014;14(s1):210–1.

Summary of product characteristics. Zebinix® (eslicarbazepine acetate). Portugal: BIAL–Portela & Ca S.A., S. Mamede do Coronado, Portugal; 2013.

French JA, Wang S, Warnock B, Temkin N. Historical control monotherapy design in the treatment of epilepsy. Epilepsia. 2010;51:1936–43. doi: 10.1111/j.1528-1167.2010.02650.x. PubMed DOI

Baulac M, Brodie MJ, Patten A, Segieth J, Giorgi L. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2012;11:579–88. doi: 10.1016/S1474-4422(12)70105-9. PubMed DOI

Kwan P, Brodie MJ, Kälviäinen R, Yurkewicz L, Weaver J, Knapp LE. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol. 2011;10:881–90. doi: 10.1016/S1474-4422(11)70154-5. PubMed DOI

Leber PD. Hazards of inference: the active control investigation. Epilepsia. 1989;30(s1):64–8. doi: 10.1111/j.1528-1157.1989.tb05816.x. PubMed DOI

Sperling M, Harvey J, Blum D, Grinnell T. Conversion to monotherapy with eslicarbazepine acetate in adults with partial-onset seizures - results of a North-American study. Abst. 3.293. Epilepsy Curr. 2014;14(s1):431–2.

Commission on Classification and Terminology of the International League Against Epilepsy (ILAE) Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981;22:489–501. doi: 10.1111/j.1528-1157.1981.tb06159.x. PubMed DOI

Borghs S, de la Loge C, Cramer A. Defining minimally important change in QOLIE-31 scores: Estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures. Epilepsy Behav. 2012;23:230–4. doi: 10.1016/j.yebeh.2011.12.023. PubMed DOI

Duru G, Fantino B. The clinical relevance of changes in the Montgomery-Asberg depression rating scale using the minimum clinically important difference approach. Curr Med Res Opin. 2008;24:1329–35. doi: 10.1185/030079908X291958. PubMed DOI

French JA, Temkin NR, Shneker BF, Hammer AE, Caldwell PT, Messenheimer JA. Lamotrigine XR conversion to monotherapy: first study using a historical control group. Neurotherapeutics. 2012;9:176–84. doi: 10.1007/s13311-011-0088-3. PubMed DOI PMC

Boggs JG, Nowack WJ, Drinkard CR. Analysis of the “honeymoon effect” in adult epilepsy patients. Epilepsia. 2000;41(Suppl. 7):222. PubMed

Kutlu G, Gomceli YB, Erdal A, Inan LE. The honeymoon effect in adult patients with refractory partial-onset epilepsy under levetiracetam add-on treatment. Epilepsia. 2013;19:15–8. doi: 10.5505/epilepsi.2013.48568. DOI

Loscher W, Schmidt D. Experimental and clinical evidence of loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia. 2006;47:1253–84. doi: 10.1111/j.1528-1167.2006.00607.x. PubMed DOI

Chung S, Ceja H, Gawłowicz J, Avakyan G, McShea C, Schiemann J, et al. Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study. Epilepsy Res. 2012;101:92–102. doi: 10.1016/j.eplepsyres.2012.03.007. PubMed DOI

Wechsler RT, Li G, French J, O’Brien TJ, D’Cruz O, Williams P, Goodson R, Brock M, the ALEX-MT Study Group et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: Results from a historical-controlled, multicenter, double-blind study. Epilepsia. 2014;55(7):1088–98. doi: 10.1111/epi.12681. PubMed DOI PMC

French JA, Kwan P, Fakhoury T, Pitman V, DuBrava S, Knapp L, Yurkewicz L, et al. Pregabalin monotherapy in patients with partial-onset seizures. A historical-controlled trial. Neurology. 2014;82(7):590–7. doi: 10.1212/WNL.0000000000000119. PubMed DOI PMC

WHO Collaborating Center for Drug Statistics Methodology. ATC/DDD Index [http://www.whocc.no/atc_ddd_index/]. Accessed March 19, 2014.

Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies

See more in PubMed

EudraCT
2010-018684-42

ClinicalTrials.gov
NCT01091662